PD46-03 EXAMINING MINORITY ENROLLMENT IN CLINICAL TRIALS IN UROLOGIC ONCOLOGY

Abstract

You have accessJournal of UrologyHealth Services Research: Practice Patterns, Quality of Life and Shared Decision Making IV (PD46)1 Sep 2021PD46-03 EXAMINING MINORITY ENROLLMENT IN CLINICAL TRIALS IN UROLOGIC ONCOLOGY Jeunice Owens-Walton, Cheyenne Williams, Alexis Rompre-Brodeur, Peter Pinto, and Mark W. Ball Jeunice Owens-WaltonJeunice Owens-Walton More articles by this author , Cheyenne WilliamsCheyenne Williams More articles by this author , Alexis Rompre-BrodeurAlexis Rompre-Brodeur More articles by this author , Peter PintoPeter Pinto More articles by this author , and Mark W. BallMark W. Ball More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002060.03AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Adequate representation in clinical trials is an important step towards addressing healthcare inequities. To explore the state of clinical trial representation within urologic cancers, we conducted a retrospective analysis comparing racial demographics in NIH-funded clinical trials with national cancer prevalence. METHODS: The ClinicalTrials.gov results database was queried for completed and resulted phase II and III, interventional clinical trials in the US funded by the NIH in prostate, kidney and bladder cancer. The Surveillance, Epidemiology, and End Results (SEER) database was queried for the prevalence of prostate, kidney and bladder cancer cases between 2000 and 2017. Representation Quotients (RQ) were calculated to describe the relative proportion of each demographic enrolled in a clinical trial over the proportion of those groups among national cancer cases. RESULTS: Seventy-five clinical trials met inclusion criteria with 59 of these reporting race and ethnicity. RQs were calculated for each race and ethnicity across each cancer type. Aggregates from 2000 to 2017 showed that White patients were overrepresented in trials for all cancer types (bladder cancer: RQ = 1.13 [1.11-1.15], kidney cancer: 1.28 [1.25-1.32], prostate cancer: 1.18 [1.16-1.20]). Black patients were adequately represented in prostate trials (0.95 [0.85-1.04] but underrepresented in kidney and bladder (0.75 [0.55-0.95] and 0.45 [0.26-0.64]). Asian patients were underrepresented in kidney and prostate trials (0.37 [0.22-0.51] and 0.67 [0.91 – 0.43]). Hispanic patients were underrepresented in kidney and prostate trials (0.52 [0.42 – 0.61] and 0.81[0.65-0.96], respectively). When stratified by 4-year increments and the RQs remained stable for all races, across all years in the study period. CONCLUSIONS: NIH funded clinical trials targeting prostate, kidney and bladder cancers continue to underrepresent minority patients. Based on the incidence of these cancers within minority populations there need to be improved and targeted efforts focused on creating racially and ethnically inclusive cancer research. Source of Funding: NIH Intramural Research Funding, NIH Medical Research Scholars Program, Foundation for the NIH © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e749-e749 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jeunice Owens-Walton More articles by this author Cheyenne Williams More articles by this author Alexis Rompre-Brodeur More articles by this author Peter Pinto More articles by this author Mark W. Ball More articles by this author Expand All Advertisement Loading ...